Tagged with Investment

Greece Longstanding J&J Greece Managing Director Theodore Liakopoulos looks back on the progress that Greek healthcare has made in the past four years, thanks in no small part to the commitment of the multinational medtech industry. Liakopoulos highlights the importance of establishing a centralised procurement authority for the sustainability of Greek…

Greece Since 2020, IQVIA has established health economics, technology, and market research hubs in Greece, leveraging the country’s talent pool to serve a range of EMEA markets. Nikos Kostaras outlines what else Greece has to offer to IQVIA, as well as the key services that the firm brings to its Greek…

China In light of ongoing geopolitical tension, a globally unfavourable macroeconomic environment and new drug-pricing legislation in the US, at the recent BIO CEO and Investor Conference industry stakeholders evaluated the risks and the opportunities for cross-border deal-making between US and China and found a number of reasons to be optimistic.…

France Despite an uncertain macro-economic environment, the French health technology sector continues its growth trajectory, demonstrating both entrepreneurial dynamism and maturity, according to the new edition of the France Biotech study encompassing French startups in biotech, medtech and digital health.   France Biotech, the French association for innovation in healthcare, has…

Belgium While only Europe’s 34th biggest country by landmass and 13th by population, Belgium punches well above its weight in terms of key life sciences industry indicators, notably placing in the Top Five European countries for pharma R&D spending, pharma exports, and pharma imports. Made with Visme Infographic Maker   Made…

LatAm Sarah Aiosa oversees the entire Latin America region for MSD, where the global giant is looking to build on its 100-year legacy by better addressing the continent’s health inequities and unmet medical needs. Aiosa describes the myriad public-private partnerships that the firm has struck in LatAm across areas including cancer…

Taiwan In just 35 years, Taiwan has gone from having no biotechs on the TAIEX and Taiwan OTC stock exchanges to 124 listed firms with a combined market capitalization of more than USD 30 billion by 2020, as the below chart from the Carnegie Endowment for International Peace shows. In 2019,…

Egypt Barely four and a half years ago, Egyptian President Abdel Fattah el-Sisi secured overwhelming re-election vowing to “place public health front and centre” of a radical reform and stabilization agenda. What has occurred subsequently has undoubtedly been momentous. Firstly, his administration unveiled ambitious plans to provide universal, cradle to grave,…

Global David H. Crean, Managing Partner for Cardiff Advisory, highlights the tone and tenor of J.P. Morgan’s recent 2023 Healthcare Conference held in San Francisco in light of the uncertain economic environment that saw fewer IPOs in 2022 than in previous years and numerous negative enterprise value companies trading below cash…

USA Initial public offerings (IPOs) —a vital source of cash for up-and-coming biotechs— saw a huge decline in 2022 with respect to the previous year. After 2021’s record of more than 100 biotech IPOs that raised almost USD 15 billion in funds, 2022 saw a mere 17 biotechnology companies launch IPOs…

Germany Home to Europe’s largest pharma market, a host of industry giants, a thriving biotech scene, and a public healthcare system undergoing significant reform, Germany is indisputably one of the world’s most important life science nations.   An overview of the pharma industry in Germany. Made with Visme Infographic Maker   The…

LatAm Yaneth Giha of FIFARMA – the leading association for the innovative pharmaceutical industry in Latin America – gives a bird’s-eye overview on some of the key trends in LatAm healthcare, from regulatory and access challenges to the impact of the COVID-19 pandemic, the region’s potential as a clinical trials hub,…